This article was originally published in the Washington Examiner by Elaine Mallon Jason Raubach was diagnosed at 50 years old with early-onset Alzheimer’s disease — a diagnosis that affects nearly 200,000 Americans. He received the diagnosis in 2018, completely upending life for his family. His youngest child was just a freshman in high school. “It’s like somebody grabs you by […]
For immediate release: Contact: media@globalalzplatform.org Washington D.C., May 20, The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA’s clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s—a critical […]
BY SETH VOORHEES OSWEGO | spectrumlocalnews OWEGO, N.Y. — Nearly seven million Americans live with Alzheimer’s disease, and according to the National Institutes of Health, the number could grow by 50% by 2060. It’s a stunning number, but researchers say they’re making great progress in understanding and preventing the disease, which affects memory, thinking and behavior. An author and […]
By Christopher Placek – Daily Herald More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s disease, researchers at Ascension Alexian Brothers hospital in Elk Grove Village are now studying potential new treatments to address the neurological disorder. “We have these two very interesting studies […]
By Aging Research, Published March 10, 2025 Aging Research The Alliance for Aging Research, the Partnership to Fight Chronic Disease (PFCD), and the Global Alzheimer’s Platform Foundation (GAP) submitted comments today on both of the recently issued draft guidances on accelerated approval—Expedited Programs for Serious Conditions—Accelerated Approval of Drugs and Biologics (hereafter the “Programmatic Guidance”) and Accelerated Approval and Considerations for […]
Purchase of Axiom Brain Health puts Tampa clinical trial site at center of research to find easier way to detect disease in patients. TAMPA — The most reliable way to to diagnose Alzheimer’s disease is through a positron emission tomography or PET scan of the brain, an expensive test not always covered by insurance. Another […]
His wife, Joann, is a retired nurse and also knew that research was going to be the way forward for them and for future generations. To find out about studies near you, go to K2Med.com or Fastertrials.org to find sites around the US.
‘Coming in and just answer some questions, and seeing if there’s something that needs to be investigated,’ By: Victor Jorges WPTV5 DELRAY BEACH, Fla. — A Palm Beach County research organization is helping people with their memory for free. Brain Matters Research in Delray Beach is hosting free memory screenings on Tuesday and Wednesday from 9 […]
People with Down syndrome helped scientists pave the way for Alzheimer’s drugs but are now left out of the treatment. By Hampus Hillerstrom and Jo Ann Simons The clinical trials for new Alzheimer’s disease treatment drugs — which researchers believe will slow the course of the disease over time — offer hope to thousands of […]
By Janet Lee – Washington Post Consumer Reports has no financial relationship with any advertisers on this site. Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do […]
Free, bilingual screening on World Alzheimer’s Day Intercoastal Medical Group Neurology and Research Clinic will hold a free, bilingual?memory?screening event on World Alzheimer’s Day on Sept. 21 from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex, 1845 John Rivers St., in Sarasota. The goal of the confidential? screening in English and Spanish […]
By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage […]
By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that […]
WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]
House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita […]
by Barbara Campos – Telemundo According to the conclusions of a new Alzheimer’s Association report, Hispanics are almost twice as at risk as other demographic groups, and caring for patients can place a heavy burden on households. The report illustrates the need to allocate more resources and efforts to raise awareness about a degenerative disease […]
“GAP strongly encourages ICER to revamp its model to accurately reflect Leqembi’s benefits and what matters most to patients and their families” For immediate release: Washington, D.C. (March 17, 2023) — Joining other Alzheimer’s advocates, experts and researchers, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer provided written comments as part of the Institute for […]
“Today, the Veterans Health Administration (VA) demonstrated enormous leadership and concern for the health of veteran’s fighting Alzheimer’s disease with its decision to cover the cost of Leqembi. Our veterans battled for us, and the VA is now giving their patients new therapies to battle Alzheimer’s.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: […]
BAY VILLAGE, Ohio — There are two newly-approved treatments to treat Alzheimer’s Disease, but getting them covered by medicare is a battle. Alzheimer’s impacts nearly 6 million Americans over the age of 65, and that number is expected to triple by 2060. It is the sixth leading cause of death in the U.S., according to […]
Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which […]
“CMS’s latest decision on disease-modifying therapies for Alzheimer’s patients is effectively a coverage denial for this entire class of drugs, and patients will needlessly die as a result of it.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 23, 2023) — “Once again, the Centers for Medicare and Medicaid Services (CMS) […]
The Global Alzheimer’s Platform Foundation’s® (GAP) 2022 Citizen Scientist Award recipients include the first husband-and-wife volunteer team, an Alzheimer’s advocate who champions participation in prevention studies, and a Parkinson’s disease clinical trial participant who volunteers in research studies to find hope after diagnosis WASHINGTON, DC (Feb. 22, 2023) — Today, the Global Alzheimer’s Platform Foundation […]